

# Rivaroxaban and early periprosthetic joint infection: our experience

*Paolo Di Benedetto, Andrea Zangari, Dania De Franceschi, Enrico Daniele Di Benedetto, Vanni Cainero, Alessandro Beltrame, Renato Gisonni, Araldo Causero*

Clinic of Orthopaedics, Academic Hospital of Udine, Italy

**Summary.** *Background and aim of the work:* Periprosthetic joint infection (PJI) is a severe post-operative complication after Primary Total Hip Arthroplasty (THA). According to the classification of PJI early acute PJI occurs within 4 weeks from surgery. Some authors think that Rivaroxaban is a risk factor in the incidence of early acute PJI. We analyze our experience about this item. *Materials and methods:* We analyze our experience from 1st January 2015 to 31st December 2016. We consider all consecutive hip arthroplasty implants in this period. *Results:* In the 205 patients analysed we not find early acute PJI in Rivaroxaban group nor in the others assuming another kind of thromboprophylaxis. *Conclusions:* In our series there is no evidence of association between Rivaroxaban and early acute PJI. This is a retrospective cohort study, so we need more studies and more robust experimental designs to confirm these results. ([www.actabiomedica.it](http://www.actabiomedica.it))

**Key words:** acute early periprosthetic joint infection, Rivaroxaban, Total Hip Arthroplasty

## Introduction

Periprosthetic joint infection (PJI) is a severe post-operative complication after Primary Total Hip Arthroplasty (THA) (1, 2). PJI over the hip arthroplasty is a very rare event, but its incidence increased from 1,99% to 2,18% from 2001 to 2009 (3) and we expect that the percentage will increase again according to the rising number of total hip arthroplasty. Culliford et al. estimate that the number of total hip arthroplasty (THA) will increase of 91,75% from 2010 to 2035 in UK (4); similarly, in USA according to the prevision of Kurtz et al. the number of total hip arthroplasty (THA) will increase of 174% from 2005 to 2030 (5).

After Tsukayama (6) and Trampuz (7) classification, recently early periprosthetic joint infection has been defined as an infection that occurs within 4 weeks after surgery (8, 9) and usually manifests with acute

joint pain, wound inflammation (warmth and erythema), joint effusion, and loss of function (10). Most early PJI is caused by Gram-positive cocci (Staphylococcus aureus and coagulase-negative Staphylococcus) (11, 12).

Instead of late PJI, the treatment of early periprosthetic joint infection can save the implant. The treatment consists in irrigation and debridement including liner exchange and antibiotic therapy. In case of failure of the previous treatment we must proceed more aggressively with one or two stage revision, Girdlestone, arthrodesis or amputation in severe cases (13-16).

The most common risk factors of PJI are obesity, low BMI, diabetes mellitus, hyperglycaemia around surgery even in patients without diabetes, rheumatoid arthritis, immunosuppressive therapy, malignancy, distant site infections, elevated ASA score. There are others risk factors linked with intraoperative and

post-operative factors that seems to increase the incidence of PJI, like prolonged time of operation, use of allogenic blood transfusions and especially for acute infection hematoma, superficial surgical site infection, wound complications like drainage and wound dehiscence (17-19).

Among the many risk factors of periprosthetic joint infection, post-surgery anticoagulants may have a role. Routine thromboprophylaxis with anticoagulants after THA is strongly recommended by the national guidelines of The American College of Chest Physicians (20). Nowadays, in orthopaedist surgery, we can choose between different kind of molecules such as low molecular weight heparin (LMWH), Warfarin, Enoxaparin, Fondaparinux, Rivaroxaban, Dabigatran, Apixaban etc.

Rivaroxaban is a direct-acting oral anticoagulant (DOAC). It is the first available orally active direct factor Xa inhibitor. Rivaroxaban inhibits both free factor Xa and factor Xa bound in the prothrombinase complex (21). Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. The convenience of oral use and the potential absence of thrombocytopenia adverse effect are the best advantages (22).

Currently the Authors do not agree about a real association between Rivaroxaban and early deep post-operative surgical site infection after primary THA and TKA.

In this study, we wanted to verify if Rivaroxaban has increased the number of early PJI in patients undergone to total hip arthroplasty in our Clinic.

## Methods

We analyzed all consecutive patients undergone to total hip arthroplasty (THA) from 01<sup>st</sup> January 2015 to 31<sup>th</sup> December 2016. We excluded patients undergone to total knee arthroplasty (TKA) because, according to the rules of our hospital, it is not possible to prescribe this kind of thromboprophylaxis in this kind of surgery for more than 15 days.

Each patient was treated with thromboprophylaxis from 8-12 hours after surgery to 35 days post sur-

gery, according to American College of Chest Physicians guidelines, published in 2012 (20).

Patients collected were treated with Rivaroxaban, Fondaparinux, Enoxaparin, Nadroparin, Calciparin, Dabigatran, Warfarin, Acenocumarol. In patients that took Warfarin or Acenocumarol, our protocol is suspension 5 days before surgery and substitution with single or double dose of Enoxaparin; after surgery, when bleeding is controlled, patients start double therapy with heparin and Warfarin or Acenocumarol: when INR value is greater 2 for two times they could stop heparin.

In our protocol of antibiotic prophylaxis, we use cefazolin 2 g or Clindamycin 600 mg for allergic patients 30 minutes before surgery. After discharge, patients came back after 2 weeks from surgery to remove the suture, and the first clinical and radiological control was after 45 days.

## Results

We analyzed retrospectively 205 consecutive patients between 01<sup>st</sup> January 2015 to 31<sup>th</sup> December 2016. Among 205 patients operated, 145 were treated with Rivaroxaban, 25 with Fondaparinux, 19 with Oral Anticoagulants (Warfarin or Acenocumarol), 5 with Calciparin, 3 with Dabigatran, 8 with Nadroparin or Enoxaparin.


Mean age was 69,2 years old, 120 were women and 85 men, mean value of Charlson Comorbidity Index was 2,14. The medium length of stay in hospital for these patients was about 5 days.

We divided these patients into 2 groups: the Rivaroxaban group and the control one composed by patients treated with a thromboprophylaxis different from Rivaroxaban (Figs. 1, 2).


Although We used Rivaroxaban in 70,73% of patients, we registered no cases of early PJI in the group treated with Rivaroxaban nor in the control group.

## Discussion

In literature, there is a lack of consensus about a real association between Rivaroxaban and early deep



**Figure 1.** Thromboprophylaxis in our study



**Figure 2.** Different use of Rivaroxaban and other anticoagulants

postoperative surgical site infection after primary THA and TKA.

In their study, Brimmo et al. concluded that the use of Rivaroxaban for thromboprophylaxis led to a significantly increased number of deep surgical site infection with an incidence 2.5% in Rivaroxaban group (159 patients) vs 0.2% in the control one (480 patients) (23).

Another study written by Jensen et al (24) confirm this observation. The infection rate in their patients treated with Rivaroxaban after THA and TKA was similar to Brimmo et al. data, with an infection rate of 2.5% in patients treated with Rivaroxaban and 1% in those treated with Tinzaparin. Chahal et al (25) noted an increase from 0.9% to 1.9% in infection rate for 160 patients treated with Rivaroxaban after prima-

ry THA and TKA (compared with 227 treated with Enoxaparin), even if this difference did not reach statistical significance.

In their prospective cohort study evaluating postoperative wound healing, Sindali et al (26) noted a 1% deep infection rate in 202 patients who received Rivaroxaban after primary THA and TKA, which is comparable to the overall infection rate reported for primary THA and TKA in the literature (27, 28).

A previous multicenter retrospective study by Jameson et al (29) also reported a low infection rate (17 of 2762; 0.62%) in patients treated with Rivaroxaban, which was not significantly higher than the rate of their Enoxaparin control group (55 of 10,361; 0.53%).

The increased rate of infections observed in patients undergoing THA and TKA in the Brimmo et al. study contrasts with the rate of serious postoperative wound infections observed by Lassen et al (30), who reported a 0.16% rate of postoperative infection in 6183 patients who received Rivaroxaban compared with a 0.27% rate of serious postoperative infection in 6200 patients who received Enoxaparin.

Limit of this study are the retrospective design, the number of patients, the absence of incidence of early deep surgical site infections in both groups evaluated.

## Conclusions

Our experience didn't show the same trend we found in some studies in literature (23-25). In our opinion the association between Rivaroxaban and early postoperative deep surgical site infection has not been sufficiently evaluated.

We are not sure about the role of Rivaroxaban among early acute PJI. There is a lack of studies about this item. Rivaroxaban use has increased in the last few years, so further studies are required to verify its association with early periprosthetic infection.

## References

1. Lidgren L. Joint prosthetic infections: a success story. *Acta Orthop Scand* 2001; 72: 553.

2. Phillips JE, Crane TP, Noy M, et al. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective survey. *J Bone Joint Surg Br* 2006; 88: 943.
3. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic Burden of Periprosthetic Joint Infection in the United States. *The Journal of Arthroplasty*, September 2012; 27(8): 61-65.e1
4. Culliford D, Maskell J, Judge A, Cooper C, Prieto-Alhambra D, Arden NK; COAST Study Group. Future projections of total hip and knee arthroplasty in the UK: results from the UK Clinical Practice Research Datalink. *Osteoarthritis Cartilage* 2015 Apr; 23(4): 594-600.
5. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. *J Bone Joint Surg Am* 2007; 89: 780-85.
6. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. *J Bone Joint Surg Am* 1996; 78(4): 512-23.
7. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. *N Engl J Med* 2004; 351: 1645-54.
8. Koyonos L, Zmistowski B., Della Valle C J, Parvizi J. Infection control rate of irrigation and debridement for periprosthetic joint infection. *Clin Orthop Relat Res* 2011; 469: 3043-8.
9. Faschingbauer M, Kappe T, Bieger R, Reichel H, Retention of the prosthesis in early periprosthetic infection after total hip arthroplasty, *Z Orthop Unfall*, 2015 Apr; 153(2): 192-7.
10. Parvizi J, Zmistowski B, Berbari EF, Bauer TW, Springer BD, Della Valle CJ, et al. New definition for periprosthetic joint infection: From the Workgroup of the Musculoskeletal Infection Society. *Clin Orthop Relat Res* 2011; 469: 2992-4.
11. Phillips JE, Crane TP, Noy M, Elliott TS, Grimer RJ. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: A 15-year prospective survey. *J Bone Joint Surg Br* 2006; 88: 943-8.
12. Fulkerson E, Valle CJ, Wise B, Walsh M, Preston C, Di Cesare PE. Antibiotic susceptibility of bacteria infecting total joint arthroplasty sites. *J Bone Joint Surg Am* 2006; 88: 1231-7.
13. Di Benedetto P, Di Benedetto ED, Buttironi MM, De Franceschi D, Beltrame A, Gisonni R, Cainero V, Causero A. Two-stage revision after total knee arthroplasty. *Acta Biomed* 2017 Jun 7; 88(2-S): 92-7.
14. Di Benedetto P, Di Benedetto ED, Salviato D, Beltrame A, Gisonni R, Cainero V, Causero A. Acute periprosthetic knee infection: is there still a role for DAIR? *Acta Biomed* 2017 Jun 7; 88(2-S): 84-91.
15. Di Benedetto P, Povegliano L, Cainero V, Gisonni R, Beltrame A, Causero A. The role of intraoperative frozen section in arthroplasty revision surgery: our experience. *Acta Biomed* 2016 Apr 15; 87 Suppl 1: 34-40
16. Bassetti M, Cadeo B, Villa G, Sartor A, Cainero V, Causero A. *J Antimicrob Chemother*. Current antibiotic management of prosthetic joint infections in Italy: the 'Udine strategy'. 2014 Sep; 69 Suppl 1: 41-5.
17. Peel TN, Dowsey MM, Daffy JR, Stanley PA, Choong PF, Buising KL. Tande and Patel Risk factors for prosthetic hip and knee infections according to arthroplasty site. *J Hosp Infect* 2011; 79: 129-33.
18. Berbari EF, Osmon DR, Lahr B, Eckel-Passow JE, Tsaras G, Hanssen AD, Mabry T, Steckelberg J, Thompson R. The Mayo prosthetic joint infection risk score: implication for surgical site infection reporting and risk stratification. *Infect. Control Hosp Epidemiol* 2012; 33: 774-81.
19. Namba RS, Inacio MC, Paxton EW. Risk factors associated with surgical site infection in 30,491 primary total hip replacements. *J Bone Joint Surg Br* 2012; 94: 1330-8.
20. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; 141(2 Suppl): e278S-325S.
21. Roehrig S, Straub A, Pohlmann J, et al. "Discovery of the novel antithrombotic agent 5-chloro-N-(((5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor". *Journal of Medicinal Chemistry* 48 (19): 5900-8.
22. Di Benedetto P, Vetrugno L, DE Franceschi D, Gisonni R, Causero A, Rocca GD. Patient compliance with new oral anticoagulants after major orthopaedic surgery: rivaroxaban and dabigatran compared with subcutaneous injection of fondaparinux. *Joints* 2017 Feb 7; 4(4): 214-221.
23. Brimmo O, Glenn M, Klika AK, et al. Rivaroxaban use for thrombosis prophylaxis is associated with early periprosthetic joint infection. *J Arthroplasty* 2016; 31: 1295.
24. Jensen CD, Steval A, Partington PF, et al. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. *J Bone Joint Surg Br* 2011; 93: 91.
25. Chahal GS, Saithna A, Brewster M, et al. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis. *Ortop Traumatol Rehabil* 2013; 15: 125.
26. Sindali K, Rose B, Soueid H, et al. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. *Eur J Orthop Surg Traumatol* 2013; 23: 481.
27. Lehtimäki MY, Kautiainen H, Lehto UK, et al. Charnley low-friction arthroplasty in rheumatoid patients: a survival study up to 20 years. *J Arthroplasty* 1999; 14: 657.
28. Fender D, Harper WM, Gregg PJ. Outcome of Charnley total hip replacement across a single health region in England: the results at five years from a regional hip register. *J Bone Joint Surg Br* 1999; 81: 577.

29. Jameson SS, Rymaszewska M, Hui ACW, et al. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecularweight heparins for thromboprophylaxis in lower limb arthroplasty. *J Bone Joint Surg Am* 2012; 94: 1554.
30. Lassen MR, Gent M, Kakkar AK, et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. *J Bone Joint Surg Br* 2012; 94: 1573.

---

Received: 17 July 2017

Accepted: 26 July 2017

Correspondance:

Paolo Di Benedetto, MD, PhD

Clinica Ortopedica

Azienda Sanitaria Universitaria Intergrata di Udine

P.le S.Maria della Misericordia, 15 - 33100 Udine

Tel. +39 0432 559464

Fax +39 0432 559298

E-mail: [paolo.dibenedetto@asuiud.sanita.fvg.it](mailto:paolo.dibenedetto@asuiud.sanita.fvg.it)